Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor's clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile. The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial. The xCures platform also enables patients to find more suitable treatment options if they are ineligible.
Search
Recent Posts
See AllBy: Catherine Shu Legacy healthcare software systems are often complicated and cumbersome for providers to use, leading to less time with patients. That’s why Regard (formerly HealthTensor) developed
By: Richard Gawel In 2020, guidelines changed to encourage parents and caregivers to introduce peanut and egg to infants aged 4 months to 6 months to help prevent food allergies. Yet many parents stil
Medicare Bundles See 55-70% Cost Savings with Luna's In-Home Outpatient PT Program, New Study Reveal
Luna announced the results of a retrospective analysis which demonstrated significant financial savings for those choosing in-home outpatient physical therapy (PT) compared to traditional home health
